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TLR1/2 and 5 induce elevated cytokine levels
from rheumatoid arthritis monocytes independent
of ACPA or RF autoantibody status
Ryan S. Thwaites1, Sarah Unterberger1, Giselle Chamberlain1,
Karen Walker-Bone1, Kevin A. Davies1 and Sandra Sacre 1
Abstract
Objective. RA is an autoimmune inflammatory joint disease. Both RF and ACPA are associated with more pro-
gressive disease and higher levels of systemic inflammation. Monocyte activation of toll-like receptors (TLRs) by en-
dogenous ligands is a potential source of increased production of systemic cytokines. RA monocytes have elevated
TLRs, some of which are associated with the disease activity score using 28 joints (DAS28). The aim of this study
was to measure TLR-induced cytokine production from monocytes, stratified by autoantibody status, to assess if
their capacity to induce cytokines is related to autoantibody status or DAS28.
Methods. Peripheral blood monocytes isolated from RA patients and healthy controls were stimulated with TLR1/
2, TLR2/6, TLR4, TLR5, TLR7, TLR8 and TLR9 ligands for 18 h before measuring IL-6, TNFa and IL-10. Serum was
used to confirm the autoantibody status. Cytokine levels were compared with RF, ACPA and DAS28.
Results. RA monocytes demonstrated significantly increased IL-6 and TNFa upon TLR1/2 stimulation and IL-6 and
IL-10 upon TLR5 activation. TLR7 and TLR9 activation did not induce cytokines and no significant differences were
observed between RA and healthy control monocytes upon TLR2/6, TLR4 or TLR8 activation. When stratified by
ACPA or RF status there were no correlations between autoantibody status and elevated cytokine levels. However,
TLR1/2-induced IL-6 did correlate with DAS28.
Conclusions. Elevated TLR-induced cytokines in RA monocytes were not related to ACPA or RF status.
However, TLR1/2-induced IL-6 was associated with disease activity.
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Introduction
RA is a chronic autoimmune disease, characterized by
inflammation of the synovial joints and the production of
autoantibodies. Peripheral blood mononuclear cells
(PBMCs) infiltrate the synovial membrane releasing cyto-
kines and growth factors that induce proliferation of syn-
oviocytes and the release of matrix metalloproteases
leading to the erosion of cartilage and bone [1]. The
autoantibodies RF and ACPA are used in the clinical
diagnosis of RA. RF is not specific for RA, whereas
ACPA are highly specific, often detectable many years
prior to disease onset. However, both ACPA and RF are
associated with a more severe clinical prognosis along-
side increased systemic inflammation, especially when
both are present [2, 3]. In recent years, the potential for
a pathological role of ACPA has emerged. ACPA have
been shown to activate osteoclastogenesis, which may
in part explain their association with a more erosive dis-
ease progression [4]. Furthermore, ACPA immune com-
plexes containing citrullinated fibrinogen have been
shown to activate toll-like receptor (TLR) 4 to induce
cytokine production [5].
The potential for TLRs to promote inflammation in RA
through activation by endogenous ligands has been rec-
ognized for many years. TLRs are a family of innate im-
mune receptors that upon activation induce high levels
of pro-inflammatory cytokines. In humans, there are 10
TLRs, most of which have been associated with RA
pathogenesis in either experimental or human disease
models [6]. Although the majority of studies have
focused on TLRs expressed by cells within the inflamed
joints, TLR activation of circulating monocytes may also
have a role in joint inflammation through migration and
differentiation to macrophages and osteoclasts and they
may facilitate the systemic inflammation associated with
RA co-morbidities such as cardiovascular disease.
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Indeed, some endogenous TLR ligands are
elevated in RA patient serum, such as high mobility
group box-1 (HMGB1), which can activate TLR2, TLR4
and TLR5 [7–9]. Furthermore, TLR2, TLR7, TLR8 and
TLR9 are expressed at higher levels in RA peripheral
blood monocytes, with TLR2 and TLR4 stimulation driv-
ing increased cytokine production by monocytes and
PBMCs, respectively, from RA patients [10–13]. TLR5 has
been shown to induce monocyte chemotaxis and pro-
mote differentiation of osteoclast precursor cells into ma-
ture osteoclasts [14]. Similarly, activation of TLR7 can
lead to differentiation of CD14þ monocytes into osteo-
clasts [15]. In addition, the expression of TLR5 and TLR7
mRNA in RA patient monocytes correlates with the dis-
ease activity score using 28 joints (DAS28) [13, 16].
Although both TLR expression in RA monocyte and
autoantibody status have been linked with increased in-
flammation and disease activity, it is not known whether
this elevation in the capacity of TLRs to induce cyto-
kines is related to autoantibody status or disease sever-
ity. The aim of this study was to measure TLR-induced
cytokine secretion by peripheral blood CD14þ mono-
cytes and then associate these responses with autoanti-
body status and DAS28.
Methods
Patient samples
The study was approved by the Brighton East Research
Ethics Committee (10/H1107/8) and the NRES
Committee North West–Lancaster (14/NW/1114). It com-
plies with the Declaration of Helsinki. Patients were
diagnosed by a consultant rheumatologist guided by the
European League Against Rheumatism/American
College of Rheumatology 2010 criteria for RA and
recruited during a routine rheumatology clinic assess-
ment. RA patients and healthy controls (HC) were
recruited through the Brighton and Sussex University
Hospitals Trust. The RA patients were aged on average
56 (range 27–82) years, 69% were female, average
mean (S.D.) disease duration was 11.5 (12.3) years, 58%
were ACPA positive and 66% were RF positive. DAS28
(CRP) was recorded for 22 of the RA patients, and the
scores ranged from 1.17 to 8.68 with a mean (S.D.) of
3.888 (1.878) and a median of 3.633. Of these patients,
four were in remission (DAS28 <2.6), four had a low dis-
ease activity (DAS28 <3.2), 10 had moderate activity
(DAS28 5.1) and four had high activity (DAS28 >5.1).
Patients were receiving no DMARDs, steroids or biologic
therapies (n¼8), taking DMARDs alone (methotrexate or
sulfasalazine) (n¼7), DMARDs with hydroxychloroquine
(n¼4), DMARDs with prednisone (n¼4), tocilizumab þ
steroid (n¼ 1), anti-TNFa alone (n¼ 2), anti-TNFa with
DMARDs (n¼2), anti-TNFa with hydroxychloroquine
(n¼1) or anti-TNFa with hydroxychloroquine and ste-
roids (n¼1). HCs (n¼ 18) were on average 45 (range
26–72) years of age and 83% were female. All partici-
pants provided written informed consent.
Cell culture
Whole venous blood was collected into tubes containing
1.8 mg/ml K2EDTA (Becton Dickinson, Oxford, UK).
PBMCs were isolated using Ficoll-plaque gradients
(Cedarlane, Burlington, ON, Canada) as previously
described [17]. Monocytes were isolated from PBMCs
using CD14þ selection beads (Miltenyi Biotec, Bisley,
UK) as per the manufacturer’s instructions before being
cultured in RPMI1640 medium supplemented with 5%
(v/v) fetal calf serum (PAN-Biotec, Aidenbach, Germany)
and 1% (v/v) penicillin–streptomycin solution (PAA,
Pasching, Austria). Cells were incubated with or without
100 ng/ml PAM3CSK4 (PAM3) or 10 ng/ml flagellin
(Axxora, Exeter, UK), 1 ng/ml FSL-1, 10 ng/ml lipopoly-
saccharide (LPS), 2 lg/ml resiquimod (R-848), 2 lM
ODN2006 or 2 lM ODN2216 (Invivogen, Toulouse,
France) for 18 h at 37C, 5% CO2. The concentrations of
the TLR ligands were previously determined by titrating
each ligand to determine the threshold for maximal
activation.
Enzyme linked immunosorbent assays
The concentration of IL-6, TNFa and IL-10 were deter-
mined by enzyme linked immunosorbent assays (ELISA)
(R&D Systems, Abingdon, UK) following the manufac-
turer’s instructions. Detection was performed using
streptavidin–horseradish peroxidase (R&D systems) and
a chromogenic 3,30,5,50-tetramethylbenzidine substrate
(Serascare Life Sciences, Gaithersburg, MD, USA).
Absorbance was read and analysed at 450 nm on a
spectrophotometric plate reader (BioTek Synergy HT;
BioTek, Swindon, UK) using Gen5 version 1.08.4 soft-
ware (BioTek).
ACPA levels were measured using a cyclic citrulli-
nated peptide-3 IgG ELISA kit (Inova Diagnostics, San
Diego, CA, USA) as per the manufacturer’s instructions.
RF autoantibody status was determined using a RF IgG
ELISA kit (Abnova, Taipei, Taiwan), according to the
manufacturer’s instructions.
Rheumatology key messages
. TLR1/2 and TLR5 have an increased capability to induce cytokines in RA monocytes.
. Elevated cytokine production upon TLR activation is not associated with RF or ACPA.
. TLR1/2-induced IL-6 production from monocytes correlates with RA disease activity.
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Statistics
Mean, S.D., standard error of the mean (S.E.M.) and statis-
tical significance were calculated using GraphPad Prism
version 8.4.2 (GraphPad Software Inc., La Jolla, CA,
USA). For statistical analysis, parametric data were
compared using Student’s two tailed unpaired t-test
with Welch’s correction. Non-parametric data were
compared with a two tailed Mann–Whitney U-test.
Correlation analysis was performed to compare DAS28
with TLR-induced cytokine levels using a Pearson two-
tailed test. S.E.M. was used for pooled experimental
data. Significance is shown as ***P<0.001, **P<0.01
and *P<0.05.
Results
TLR1/2 and TLR5 activation induced higher cytokine
levels in RA monocytes
TLR2, TLR7, TLR8 and TLR9 are reported to be
expressed at higher levels in RA monocytes and both
TLR2 and TLR4 can induce elevated cytokine expression
in either RA monocytes or PBMCs [10–13]. This sug-
gested the possibility that many of these TLRs could have
increased activity in RA monocytes. To determine their
activity, the level of cytokine production in RA CD14þ
monocytes stimulated with TLR1/2, 2/6, 4, 5, 7, 7/8 and 9
ligands was compared with that of HCs. TLR1/2 and
TLR5 were found to have elevated responses in RA
monocytes (Fig. 1). TLR1/2 activation with PAM3 induced
a significantly higher level of IL-6 (P¼0.0195) and TNFa
(P¼0.0196) with a trend towards higher IL-10
(P¼0.0639), whereas TLR2/6 with FSL-1 exhibited only a
trend towards elevated IL-6 (P¼0.1536). Stimulation of
TLR5 with flagellin produced a significantly higher level of
IL-6 (P¼0.0001) and IL-10 (P¼0.0016) in RA monocytes
but there was no increase in TNFa compared with HC.
Activation of TLR2/6 with FSL-1, TLR4 with LPS and
TLR7/8 with R-848 induced IL-6, TNFa and IL-10 secre-
tion at a comparable level to HC monocytes (Fig. 1).
Stimulation of TLR7 with CL264 or TLR9 with ODN2006 or
ODN2216 did not induce any IL-6, TNFa or IL-10. Thus,
the response to R-848 (a TLR7/8 ligand) is most probably
mediated by TLR8 in human monocytes, as we have pre-
viously shown in another study [18].
Autoantibody status is not associated with higher
cytokine production
Although TLR1/2 and TLR5 could induce higher levels of
cytokines in RA monocytes, there was a spread of cyto-
kine levels within the patient samples, with some pro-
ducing levels comparable to HCs. As both RF and
ACPA have been associated with higher levels of sys-
temic cytokines in RA patients, the results were further
analysed to explore if there was a relationship between
autoantibody status and higher TLR-induced cytokine
production [3]. When subdivided by ACPA status, there
was no significant difference in the production of IL-6,
TNFa or IL-10 upon stimulation of TLR1/2 or TLR5
(Fig. 2A). Similarly, when divided by RF status, there
was also no change in the levels of IL-6, TNFa or IL-10
in RA monocytes activated with TLR1/2 or TLR5 ligands
(Fig. 2B).
TLR1/2-induced IL-6 correlates with disease activity
TLR5 mRNA expression had previously been associated
with the DAS28 [16]. Thus, to confirm if the increased
capacity of TLR1/2 and TLR5 to induce cytokines was
correlated with disease activity, the cytokine levels were
compared with DAS28. TLR1/2-induced IL-6 was signifi-
cantly correlated with DAS28 (P ¼ 0.0365) but TNFa
and IL-10 were not (Fig. 2C). None of the cytokines
measured after TLR5 activation significantly correlated
with DAS28 (Fig. 2D).
Discussion
As both autoantibody status and TLRs have been asso-
ciated with elevated inflammation and disease severity
in RA, this study investigated whether there was a link
between elevated levels of TLR-induced cytokines in
peripheral blood CD14þ monocytes and RF or ACPA
status. An increased capacity for monocytes to produce
pro-inflammatory cytokines in the peripheral blood may
reflect early changes in their phenotype prior to infiltrat-
ing the synovium and have implications for the develop-
ment of extra-articular symptoms.
Upon TLR1/2 stimulation, significantly higher levels of
IL-6 and TNFa were observed from the RA monocytes.
This was not unexpected, as TLR2 has previously been
reported to be expressed at a higher level on RA mono-
cytes and stimulation with lipoteichoic acid (a TLR2 lig-
and that can activate both TLR1/2 and TLR2/6
heterodimers) could induce elevated levels of intracellu-
lar cytokines, as shown by flow cytometry [12]. Here,
the data confirm this finding and further demonstrate
that this elevated response when compared with HC
monocytes may be predominantly from the TLR1/2 het-
erodimer, as TLR2/6 activation (with FSL-1) only dis-
played a trend towards elevated IL-6.
Interestingly, despite reports of higher expression of
TLR4, TLR7, TLR8 and TLR9 in RA monocytes, no dif-
ference in cytokine expression was observed between
RA and HC monocytes upon activation of these TLRs.
In fact, TLR7 and TLR9 did not produce any IL-6, TNFa
or IL-10. However, this does not exclude a contribution
of these TLRs on monocytes to RA pathogenesis, as
they may induce other inflammatory mediators not
measured in this study or mediate other effects such as
differentiation of CD14þ monocytes into osteoclasts, as
has been reported for TLR7 [15]. However, our finding
that the TLR4 responses were comparable to HC mono-
cytes differs from another study, which demonstrated
elevated TLR4-induced IL-6 and TNFa production in leu-
kocytes from early onset RA patients [11]. This differ-
ence may partly be due to the larger sample size used
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FIG. 1. TLR1/2 and TLR5 induce elevated cytokine production by RA monocytes
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Monocytes from healthy controls (HC) (n¼16–18) and RA patients (n¼ 29–32) were either unstimulated (US) or
stimulated with 100 ng/ml PAM3CSK4 (PAM3), 1 ng/ml FSL-1, 10 ng/ml lipopolysaccharide (LPS), 10 ng/ml flagellin or
2 lg/ml resiquimod (R-848) for 18 h. The levels of IL-6 (A), TNFa (B) and IL-10 (C) were measured in the supernatant.
***P < 0.001, **P < 0.01 and *P < 0.05.
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in our study and the use of purified CD14þ cells rather
than a mixed cell population or could reflect differences
between early RA and more established disease.
Previously, a greater percentage of CD14þ monocytes
have been shown to express TLR5 in RA monocytes
compared with HC [16]. Although our study
FIG. 2 TLR1/2- and TLR5-induced cytokines do not associate with autoantibody status but TLR1/2-induced IL-6
correlates with DAS28.
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RA monocytes were either unstimulated (US) or stimulated with 100 ng/ml PAM3CSK4 (PAM3) or 10 ng/ml flagellin for
18 h. IL-6, TNFa and IL-10 were measured in the supernatants and compared by ACPA status (A; ACPAþ: n¼ 14,
ACPA–: n¼ 10) and RF status (B; RFþ: n¼20, RF–: n¼10–11). The data were then analysed for association with the
disease activity score using 28 joints (DAS28) in PAM3- (C; n¼22) and flagellin- (D; n¼22) stimulated monocytes.
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demonstrated a significant elevation of IL-6 and IL-10
upon activation of TLR5 in RA monocytes, which may
be expected if a greater number of cells are expressing
TLR5, the level of TNFa was similar to that of HC mono-
cytes. This suggests that the explanation for the ele-
vated IL-6 and IL-10 may be more complex than a
simple increase in receptor expression; instead, there
may be more subtle changes in the downstream regula-
tion of TLR5 signalling in RA monocytes. A similar situ-
ation has previously been reported in RA synovial
macrophages where TLR2 and TLR4 expression did not
correlate with increased levels of cytokine production,
whereas a correlation was observed in HC macrophages
[19]. The explanation for the increased cytokine produc-
tion from TLR1/2, TLR2/6 and TLR5, but not from TLR4
or TLR8, is unclear. All of these TLRs activate the down-
stream myeloid differentiation primary response 88
(MyD88) signalling pathway to induce TNF, IL-10 and IL-
6, a pathway that is shared by all of the TLR family apart
from TLR3 [20]. This would suggest that there could be
subtle differences in the regulation of this pathway be-
tween individual TLRs that have yet to be identified.
TLR5 mRNA expression has also been shown to cor-
relate with DAS28 in RA monocytes [16]. However, cor-
relation of cytokine production upon TLR1/2 and TLR5
stimulation with DAS28 only highlighted an association
between TLR1/2-induced IL-6 and disease activity.
Thus, the mechanism related to the increase in TLR5 ex-
pression may be independent of the mechanism under-
lying the amplification in cytokine production. A
limitation of this study is that the data were generated
using monocytes from patients receiving a mixed range
of treatment combinations, with only eight patients not
receiving any DMARDs, steroids or biologic therapies.
The DAS28 was not recorded for all of the patients in
this study and thus it was not possible to correlate
DAS28 with cytokine production in the patients not
receiving these therapies. It is also possible, that some
of the therapies could have affected the level of TLR-
induced cytokine production. However, a preliminary
analysis of the data stratified by those receiving treat-
ment compared with those who were not, produced
similar results in both groups suggesting that the under-
lying changes in downstream TLR signalling in the RA
patients are not affected by therapy (data not shown).
Overall the data presented in this study demonstrate
that TLR1/2- and TLR5-induced cytokine secretion is
elevated in RA monocytes but this increased capacity
for cytokine production is independent of autoantibody
status with only IL-6 induced by TLR1/2 associated with
disease activity.
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